Sugi Predict

Sugi Predict / Compounds / SCHEMBL6744615

SCHEMBL6744615

SCHEMBL6744615

CC(c1ccc(O)cc1)N1C(=O)c2ccccc2C1=O

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ POLB P06746 2/20 0.49
▸ NR1H3 Q13133 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.43
▸ HTT P42858 2/20 0.43
▸ RPS6KA2 Q15349 1/20 0.42
▸ ESR1 P03372 2/20 0.42
▸ PDCD1 Q15116 1/20 0.42
▸ ESR2 Q92731 1/20 0.42
▸ CD274 Q9NZQ7 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ DNMT3A Q9Y6K1 1/20 0.42
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16321480 1.00 LMNA (0.51) LMNAPOLBNR1H3TDP1ALDH1A1
SCHEMBL14280264 0.86 POLB (0.55) LMNAPOLBALDH1A1ESR1PDCD1
SCHEMBL10926240 0.85 ALDH1A1 (0.51) LMNAPOLBTDP1ALDH1A1HTT
SCHEMBL16356142 0.85 ALDH1A1 (0.51) LMNAPOLBTDP1ALDH1A1HTT
SCHEMBL6925572 0.85 LMNA (0.58) LMNAPOLBTDP1ALDH1A1TP53
SCHEMBL607042 0.85 LMNA (0.58) LMNAPOLBTDP1ALDH1A1TP53
SCHEMBL29393294 0.85 LMNA (0.58) LMNAPOLBTDP1ALDH1A1TP53
SCHEMBL12845880 0.82 KMT2A (0.55) LMNATDP1
SCHEMBL2002904 0.82 LMNA (0.47) LMNAPOLBTDP1ALDH1A1HTT
SCHEMBL31706143 0.82 LMNA (0.47) LMNAPOLBTDP1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040086983-A1 Method for producing a heterocyclic compound and an aromatic carboxylic acid having one or more hydroxyl groups, and modified aromatic ring dioxygenase MARINE BIOTHECHNOLOGY INSTITUTE., LTD. (JP) 2004-05-06 — — US claimed
EP-4744664-A2 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS MyoKardia, Inc. (US) 2026-05-20 — — EP disclosed
US-20240382486-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2024-11-21 — — US disclosed
US-RE50050-E1 Pyrimidinedione compounds MyoKardia, Inc. (US) 2024-07-23 — — US disclosed
CN-109384729-B Pyrimidinedione compounds for cardiac disorders 迈奥卡迪亚公司 2023-06-30 — — CN disclosed
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2023-06-01 — — US disclosed
US-20210346379-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2021-11-11 — — US disclosed
US-20200297726-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2020-09-24 — — US disclosed
EP-3702352-A1 PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS Myokardia, Inc. (US) 2020-09-02 — — EP disclosed
EP-3010910-B1 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS MYOKARDIA INC (US) 2020-02-05 — — EP disclosed
US-20180311242-A1 PYRIMIDINEDIONE COMPOUNDS MYOKARDIA INC (US) 2018-11-01 — — US disclosed
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2017-10-05 — — US disclosed
US-9585883-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2017-03-07 — — US disclosed
EP-3010910-A1 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS Myokardia, Inc. (US) 2016-04-27 — — EP disclosed
US-20160030428-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2016-02-04 — — US disclosed
US-9181200-B2 Pyrimidinedione compounds MyoKardia, Inc. (US) 2015-11-10 — — US disclosed
US-20140378464-A1 PYRIMIDINEDIONE COMPOUNDS MyoKardia, Inc. 2014-12-25 — — US disclosed
WO-2014205223-A1 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS MyoKardia, Inc. (US) 2014-12-24 — — WO disclosed
US-20040086983-A1 Method for producing a heterocyclic compound and an aromatic carboxylic acid having one or more hydroxyl groups, and modified aromatic ring dioxygenase MARINE BIOTHECHNOLOGY INSTITUTE., LTD. (JP) 2004-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210346379-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD LMNA 401/4885POLB 111/4885NR1H3 3469/4885
US-20140378464-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD LMNA 401/4885POLB 111/4885NR1H3 3469/4885
US-20240382486-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD LMNA 401/4885POLB 111/4885NR1H3 3469/4885
US-20160030428-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD LMNA 401/4885POLB 111/4885NR1H3 3469/4885
US-20170281626-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD LMNA 401/4885POLB 111/4885NR1H3 3469/4885
US-20230165860-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD LMNA 401/4885POLB 111/4885NR1H3 3469/4885
US-20180311242-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD LMNA 401/4885POLB 111/4885NR1H3 3469/4885
US-20200297726-A1 PYRIMIDINEDIONE COMPOUNDS TYMS, TYMP, DPYD LMNA 401/4885POLB 111/4885NR1H3 3469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.